Canada markets closed

Satellos Bioscience Inc. (MSCL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.5700+0.0200 (+3.64%)
At close: 02:53PM EDT

Satellos Bioscience Inc.

65 Front Street East
Suite 201
Toronto, ON M5E 1B5
Canada
647 660 1780
https://satellos.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Francis Gleeson B.B.A. M.B.ACo-Founder, CEO, Pres & Director233.33kN/A1955
Dr. Michael A. Rudnicki Ph.D.Co-Founder & Chief Scientific Officer98kN/A1961
Mr. Warren Whitehead C.M.A., CPAChief Financial Officer46.13kN/A1952
Mr. William Wasyl JaroszExec. Director162.27kN/A1956
Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPAStrategic Advisor44.48kN/A1960
Mr. J. Robert Hall CFAVP of Fin. & Admin.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

Corporate Governance

Satellos Bioscience Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.